COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,784 Articles (22,523 medRxiv, 8,261 bioRxiv)

Most recent first Previous |  Page 2533: Articles 25321-25330  | Next

Mechanism and inhibition of SARS-CoV-2 PLpro
Klemm, T., Ebert, G., Calleja, D. J., Allison, C. C., Richardson, L. W., Bernardini, J. P., Lu, B. G. C., Kuchel, N. W., Grohmann, C., Shibata, Y., Gan, Z. Y., Cooney, J. P., Doerflinger, M., Au, A. E., Blackmore, T. R., Geurink, P. P., Ovaa, H., Newman, J., Riboldi-Tunnicliffe, A., Czabotar, P. E., Mitchell, J. P., Feltham, R., Lechtenberg, B. C., Lowes, K. N., Dewson, G., Pellegrini, M., Lessene, G., Komander, D.
10.1101/2020.06.18.160614 — Posted: 2020-06-19 Discussion: Onsite
Development of a SARS-CoV-2 total antibody assay and the dynamics of antibody response over time in hospitalized and non-hospitalized patients with COVID-19
Vogelzang, E. H., Loeff, F. C., Derksen, N. I., Kruithof, S., Ooijevaar-de Heer, P., van Mierlo, G., Linty, F., Mok, J. Y., van Esch, W., de Bruin, S., Vlaar, A. P., Seppen, B., Leeuw, M., van Oudheusden, A. J., Buiting, A. G., Jim, K. K., Vrielink, H., Swaneveld, F., Vidarsson, G., van der Schoot, C. E., Wever, P., Li, W., van Kuppeveld, F. J., Murk, J.-L., Bosch, B. J., Wolbink, G. J., Rispens, T.
10.1101/2020.06.17.20133793 — Posted: 2020-06-19
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis of confounder-adjusted 20212 hospitalized patients
Kim, M. S., An, M. H., Kim, W. J., Hwang, T.-H.
10.1101/2020.06.15.20132407 — Posted: 2020-06-19
Routine laboratory blood tests predict SARS-CoV-2 infection using machine learning
Yang, H. S., Vasovic, L. V., Steel, P., Chadburn, A., Hou, Y., Racine-Brzostek, S. E., Cushing, M., Loda, M., Kaushal, R., Zhao, Z., Wang, F.
10.1101/2020.06.17.20133892 — Posted: 2020-06-19
Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France
Sbidian, E., Josse, J., Lemaitre, G., Mayer, I., Bernaux, M., Gramfort, A., Lapidus, N., Paris, N., Neuraz, A., Lerner, I., Garcelon, N., Rance, B., Grisel, O., Moreau, T., Bellamine, A., Wolkenstein, P., Varoquaux, G., Caumes, E., Lavielle, M., Mekontso Dessap, A., Audureau, E.
10.1101/2020.06.16.20132597 — Posted: 2020-06-19 Discussion: Onsite
Leveraging wearable technology to predict the risk of COVID-19 infection.
Miller, D. J., Capodilupo, J. V., Lastella, M., Sargent, C., Roach, G. D., Lee, V. H., Capodilupo, E. R.
10.1101/2020.06.18.20131417 — Posted: 2020-06-19
Assessing the impact of coordinated COVID-19 exit strategies across Europe
Ruktanonchai, N. W., Floyd, J., Lai, S., Ruktanonchai, C. W., Sadilek, A., Rente-Lourenco, P., Ben, X., Carioli, A., Gwinn, J., Steele, J., Prosper, O., Schneider, A., Oplinger, A., Eastham, P., Tatem, A. J.
10.1101/2020.06.16.20132688 — Posted: 2020-06-19
Analysis of Genetic Host Response Risk Factors in Severe COVID-19 Patients
Taylor, K., Das, S., Pearson, M., Kozubek, J., Pawlowski, M., Jensen, C. E., Skowron, Z., Moller, G. L., Strivens, M., Gardner, S.
10.1101/2020.06.17.20134015 — Posted: 2020-06-19
Statistical Issues and Lessons Learned from COVID-19 Clinical Trials with Lopinavir-Ritonavir and Remdesivir
Yin, G., Zhang, C., Jin, H.
10.1101/2020.06.17.20133702 — Posted: 2020-06-19
A novel comprehensive metric to assess COVID-19 testing outcomes: Effects of geography, government, and policy response
Kuster, A. C., Overgaard, H. J.
10.1101/2020.06.17.20133389 — Posted: 2020-06-19

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).